Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis.

"Declarations Ethics approval and consent to participateAll experiments were performed in accordance with the ARRIVE guidelines 2.0 [32], with the German legislation on protection of animals and with approval of the local animal welfare committee (Thüringer Landesamt für Lebensmittelsicherheit und Verbraucherschutz). Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding Open Access funding enabled and organized by Projekt DEAL. Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Jena (N.M., N.S., J.W., H-Y.C.). Center for Sepsis Control and Care (J.W., H-Y.C., C.G.). German Research Council (GE2519/8-1, GE2519/9-1, C.G.). Schilling Foundation (C.G.). German Center for Mental Health; Center for Intervention and Research on adaptive and maladaptive brain Circuits underlying mental health (C-I-R-C), Jena-Magdeburg-Halle, Germany (C.G.)"